Small cell lung cancer (SCLC) at advanced stage is considered an incurable disease. Despite good response to initial chemotherapy, the responses in SCLC patients with metastatic disease are of short duration and resistance inevitably occurs. Although several target-specific drugs have altered the paradigm of treatment for many other cancers, we have yet to witness a revolution of the same magnitude in SCLC treatment. Anthracyclines, such as doxorubicin, have definite activity in this disease, and ganetespib has shown promising activity in preclinical models but underwhelming activity as a single agent in SCLC patients. Using SCLC cell lines, we demonstrated that ganetespib (IC50: 31 nM) was much more potent than 17-allylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin derivative (IC50: 16 mM). Ganetespib inhibited SCLC cell growth via induction of persistent G2/M arrest and Caspase 3-dependent cell death. MTS assay revealed that ganetespib synergized with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemotherapy. Expression of receptor-interacting serine/threonine-protein kinase 1 (RIP1), a protein that may function as a pro-survival scaffold protein or a pro-death kinase in TNFR1-activated cells, was induced by doxorubicin and downregulated by ganetespib. Depletion of RIP1 by either RIP1 small interfering RNA (siRNA) or ganetespib sensitized doxorubicin-induced cell death, suggesting that RIP1 may promote survival in doxorubicin-treated cells and that ganetespib may synergize with doxorubicin in part through the downregulation of RIP1. In comparison to ganetespib or doxorubicin alone, the ganetespib þ doxorubicin combination caused significantly more growth regression and death of human SCLC xenografts in immunocompromised mice. We conclude that ganetespib and doxorubicin combination exhibits significant synergy and is efficacious in inhibiting SCLC growth in vitro and in mouse xenograft models. Our preclinical study suggests that ganetespib and doxorubicin combination therapy may be an effective strategy for SCLC treatment, which warrants clinical testing.
INTRODUCTION
Small cell lung cancer (SCLC) is an aggressive form of lung cancer accounting for B10-20% of pulmonary malignancies, strongly associated with cigarette smoking, poor survival rates and early metastatic spreading. 1, 2 Operation is seldom performed and chemotherapy coupled with chest radiotherapy in cases limited to the chest is the mainstay of treatment for this disease. Although chemotherapy has high response rates of over 50%, the median survival of SCLC is only B10-12 months for patients with extensive disease and 18-24 months for patients with limited disease. [1] [2] [3] Only B20% of patients with limited disease can be cured with chemoradiotherapy, whereas the rest of the patients eventually succumb to the disease.
In SCLC, current standard chemotherapy consists of a platinum compound (cisplatin or carboplatin) and etoposide. Doxorubicin is an effective anthracycline chemotherapeutic agent in SCLC and is widely used in the treatment of numerous other human malignancies, such as breast cancer, bladder cancer, bone and soft tissue sarcoma, multiple myeloma, and lymphoma. 4 In the past, doxorubicin has been used in regimens including cyclophosphamide and vincristine or cyclophosphamide and etoposide, 5 which have similar efficacy to platinum regimens in patients with extensive disease. 1 Recently amrubicin, a secondgeneration anthracycline derivative, has also been shown to have significant activity in SCLC. 2 Other than the intercalation with DNA and inhibition of topoisomerase II causing DNA strand breaks, doxorubicin can also induce interleukin-8 and tumor necrosis factor-alpha in SCLC. 6 The mechanisms of resistance to doxorubicin are multiple and range from overexpression of P-glycoprotein to activation of NFkB. 7 Novel agents with more selective mechanisms of action are needed in SCLC. So far, no significant activity has been recorded in SCLC with the use of tyrosine kinase inhibitors or other targeted agents, which have significant efficacy in subtypes of non-SCLC and other tumors. 8 Heat Shock Protein 90 (HSP 90) represents an appealing molecular target for the development of novel anticancer therapies. HSP90 is a chaperone protein that has multiple functions and is involved in response to stress, post-translational folding, stabilization of mutant oncogenic proteins 9 and has critical roles in cell growth, differentiation and survival. 10 Tumor cells seem more dependent on HSP90 for proliferation and survival than normal cells, as oncogenic proteins in tumor cells are often misfolded and require high HSP90 activity for correct folding. 11 Thus, tumors tend to be more sensitive to HSP90 inhibition as the latter could cause incorrect folding of oncogenic proteins, followed by proteasome-dependent degradation that leads to cell growth inhibition and death. Over the past decade, several small-molecule inhibitors of the chaperone HSP90 have been developed as potential anticancer agents. Given that numerous oncoproteins have been identified as HSP90 clients (www.picard.ch/downloads/Hsp90interactors.pdf), HSP90 inhibitors have the potential to concomitantly block multiple oncogenic pathways by the downregulation of HSP90 client proteins, such as AKT, mTOR, MAPK, epidermal growth factor receptor, ErbB2, insulin-like growth factor-I, cyclin-dependent kinase 4 12 and receptor-interacting serine/threonine-protein kinase 1 (RIP1) and so on. 13 The multitarget properties of HSP90 inhibitors have also been shown to be advantageous in terms of overcoming oncogenic signaling redundancies and drug resistance in several cancer types. 12 In this regard, HSP90 inhibition may be of particular benefit to SCLC patients as recent NextGen sequencing studies revealed that SCLC often carries multiple genetic mutations or dysfunctions. 14, 15 Ganetespib (Synta Pharmaceuticals, Lexington, MA, USA) is a novel small-molecule HSP90 inhibitor with a unique triazolone-containing chemical structure, which is different from the benzoquinone structure of the first-and second-generation HSP90 inhibitors, such as geldanamycin and its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG). 16, 17 In comparison with 17-AAG, ganetespib is more potent in inducing rapid degradation of HSP90 client proteins and sustaining longer inhibitory activity with short-time exposure. Whereas the first generation of HSP90 inhibitors was hampered by poor solubility, significant toxicity and modest efficacy as single agent, 18 ganetespib did not display evidence of cardiac, ocular or liver toxicity, observed with other HSP90 inhibitors. 16, 17, 19 Ganetespib demonstrates significant tumor growth inhibition or regression in mouse xenograft models as single agent or in combination therapy. 16, 19, 20 It has shown additive or synergistic activities with agents commonly employed to treat advanced malignances, such as taxanes 20 and etoposide. 21 Preclinical data suggest that HSP90 is the major inhibitor of apoptosis in SCLC, which makes the SCLC cells particularly sensitive to HSP90 inhibition. 22 As a single agent, ganetespib is currently in phase II clinical trial for relapsed or refractory SCLC (NCT01173523); however, preliminary results do not appear to show significant antitumor activity (Dr Leena Gandhi, personal communication).
Here, we investigated Ganetespib alone and in combination with doxorubicin in vitro and in vivo in SCLC models. We demonstrate that there is a synergistic interaction in which ganetespib potentiates doxorubicin-induced cell death in part by eliciting persistent G2/M arrest and by blocking doxorubicininduced RIP1 activation.
RESULTS

Ganetespib is more potent than 17-AAG in SCLC cell lines
We examined the single-agent potency of ganetespib in several SCLC cell lines using MTS assay. As shown in Table 1 , ganetespib was more potent than the galdanamycin derivative 17-AAG in most of the tested SCLC lines (B200-fold difference in IC50, one-way analysis of variance (ANOVA), Po0.0001). This is in line with the previous findings of others using a variety of human cell lines. 16 The superior potency of ganetespib over 17-AAG has been attributed to its higher binding affinity to HSP90 and more potent inhibition of HSP90/p23. 19 Moreover, co-crystal structure and computational analysis showed that ganetespib binds to both the closed and open conformations of the ATP pocket lid at the HSP90 N-terminus. In contrast, restricted by their larger sizes, the ansamycin analogs such as 17-AAG can only bind the ATP-binding pocket in the open conformation. 16 The lack of constrain for HSP90 ATP pocket binding may be another reason that ganetespib is more potent than 17-AAG in vitro. Ganetespib significantly inhibited SCLC cell proliferation and induced cell death in vitro as revealed by Trypan Blue Exclusion staining ( Figure 1a ). As observed in previous preclinical studies in vitro, 16 the cytotoxic effect could be observed as early as 24 h in H69 and H146 cells and 48 h in GLC4 and H82 cells, respectively.
Ganetespib induces persistent G2/M phase arrest in SCLC cells
Cell cycle analysis (Figures 1b and c) showed that ganetespib induced significant dose-dependent cell cycle arrest at the G2/M phase in H82 and GLC4 cells. The G2/M arrest was accompanied by concomitant reduction in G1-and S phase cells. Ganetespib also induced G2/M phase arrest in other SCLC cell lines N592 (Supplementary Figure S1A ), H128 and H146 tested (data not shown). Moreover, the G2/M arrest remained persistent 72 h after ganetespib washout following 30 nM ganetespib treatment for 72 h, in all three tested SCLC cell lines (GLC4, H82 and H146) (Figure 1d ). Ganetespib stays inside tumor cells even after washout (Dr Weiwen Ying, Synta Pharmaceuticals, personal communication). The observed persistent G2/M phase arrest may be, in part, because of the persistent presence of ganetespib inside the cells. It is foreseeable that the persistent G2/M arrest may contribute to the observed cell proliferation inhibition and death induced by ganetespib. These findings are consistent with similar reports in non-SCLC cells 16, 20 and confirm that ganetespib exerts strong effects in modulating cell cycle regulatory proteins that are important for its anticancer activity. 19, 23 Ganetespib is synergistic with doxorubicin in vitro We examined the concomitant combination of ganetespib with two topoisomerase II inhibitors, etoposide and doxorubicin, which have clinical activity in SCLC. MTS assay showed that the IC50 of ganetespib, doxorubicin and etoposide in H82 cells were 30, 43 and 220 nM respectively (Supplementary Table S1 ). The cell viability was analyzed by TO-PRO-3 stain in cells treated with doxorubicin, ganetespib, etoposide and the combination (ganetespib þ doxorubicin or ganetespib þ etoposide) (Figure 2A ). In comparison with single treatments (ganetespib, doxorubicin or etoposide), combination treatments (ganetespib þ doxorubicin or ganetespib þ etoposide) significantly reduced cell viability (P-values o0.05, one-way ANOVA) at all studied time points (24, 48 and 72 h). Ganetespib is synergistic with doxorubicin in SCLC CH Lai et al
The combinational activity was also assessed by the ChouTalalay method, using seven different concentrations of ganetespib þ doxorubicin or ganetespib þ etoposide combinations, in three SCLC cell lines, GLC4, H82 and H69 (Supplementary Figures 2B and S2 ). Combination indices (CI) were calculated for each dose combinations. A CIo1 indicated synergy, CI ¼ 1 indicated additivity and a CI41 indicated antagonism. A CIo1 (such as 0.234 for GLC4; 0.67 for H82) was found at low doses of ganetespib and doxorubicin, which inhibited cell growth by 470% ( Figure 2B left panel) . Similarly, a CIo1 of ganetespib and etoposide (such as 0.654 for GLC4; 0.762 for H82) also led to cell growth inhibition by 470% ( Figure 2B right panel). However, the synergistic activity was less pronounced in H69 cells (Supplementary Figure S2) .
Cytostatic effects of ganetespib þ doxorubicin combination treatment To explore the cytostatic effects of ganetespib þ doxorubicin, we examined the cell cycle distribution in cells treated with the indicated concentrations of doxorubicin, ganetespib and the combination of the two drugs. In combination studies, the cells were either treated concomitantly (drugs added at the same time) or sequentially (ganetespib was supplemented 24 h after doxorubicin treatment). Similar to H82 and GLC4 cells (Figures 1b and c) , all tested SCLC cell lines displayed G2/M phase accumulation 24 h after ganetespib treatment ( Figure 2C , Supplementary Figures S1A and S1B). N592 and H69 cells showed S-and G2/M phase accumulation 24 h after doxorubicin treatment followed by concomitant S-phase reduction and significant G2/M phase accumulation at 48-and 72-h time points (Supplementary Figures S1A and S1B), indicating that the S accumulation is not permanent, and the cells in the S phase may have died or progressed to G2/M upon the prolonged treatment. In contrast, the observed S and G2/M accumulation was more stable 48 and 72 h after doxorubicin treatment in H82 cells. In H82 cells, S phase accumulation could be observed 24 h after concomitant doxorubicin þ ganetespib combination treatment followed by S-phase reduction and significant G2/M accumulation, indicating that similar to the effect of doxorubicin treatment in N592 and H69 cells, H82 cells might also have died at the S phase or progressed from S phase to G2/M in the combination treatment. Similar pattern of S and G2/M oscillation was also observed with sequential combination treatment in N592 and H69 cells, although the S-phase oscillation was not as prominent as with concomitant treatment (Supplementary Figures S1A and S1B). Nevertheless, sequential combination treatment blocked cells at the G2/M phase as effectively as concomitant combination treatment in H82, N592 and H69 cells ( Figure 2C and Supplementary Figures S1A and S1B).
Cytotoxic effects of ganetespib and doxorubicin combination treatment To examine the cytotoxic effects of the ganetespib þ doxorubicin combination, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed. More prominent rates of TUNEL-positive cells were found in H82 cells treated with ganetespib (2.45±0.34%) or doxorubicin (3.64±0.48%) than with the vehicle (1.35 ± 0.18%). The combination treatment showed the highest rate of TUNEL-positive cells (7.29 ± 0.84%) among all the treatment groups (Po0.0001) ( Figures 2D and E Figure 3A) . However, the combination treatment did not significantly augment Caspase 3 cleavage in comparison to doxorubicin or ganetespib single-agent treatment, suggesting that part of the observed TUNEL-positive cells ( Figure 2E ) in the combination treatment might result from Caspase 3-independent cell death.
To further investigate the molecular mechanism(s) of increased TUNEL-positive cells in the combination treatment, we performed protein expression and phosphorylation profiling by reverse phase protein array (RPPA) analysis with a panel of antibodies against 113 cancer-associated proteins. 24, 25 Unsupervised hierarchical clustering analysis revealed that several canonical pathways regulating cell cycle, apoptosis/necroptosis, protein synthesis and RAS/MAPK/AKT were altered in all the treatment groups (Supplementary Figure S3A and Table 2 ). In line with the observed G2/M accumulation, Cyclin B1 (CCNB1), 26 PDK1 (PDPK1) Ser217 phosphorylation and FADD Ser194 phosphorylation 27 were consistently increased, whereas b-Catenin (CTNB1) Thr41Ser45 and Pyk2 (PTK2B) Tyr402 phosphorylations were decreased in doxorubicin, ganetespib and combination treatment groups (Table 2) . It is well established that the DNA damage repair protein poly-(ADP ribose) polymerase is cleaved and inactivated by Caspase 3/7 in Caspase 3/7-dependent apoptosis. 28 In our analysis, cleaved protein poly-(ADP ribose) polymerase was significantly augmented 48 h after the combination treatment 
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Parent cell Control siRNA 10nM RIP1 siRNA#1 10nM RIP1 siRNA#1 15nM RIP1 siRNA#4 10nM RIP1 siRNA#4 15nM ( Table 2) , and western blot analysis showed that cleaved Caspase 3 was constantly elevated in all three treatment groups ( Figure 3A) . To further discern proteins that may mediate the effects of ganetespib þ doxorubicin combination treatment, we applied our RPPA data to the Ingenuity Interactive Pathway analysis using available published protein interaction data. RIP1 (RIPK1) was found to be in the apoptosis/necroptosis networks, where it shows direct interaction with its known interacting-protein FADD 13 and chaperone HSP90 29 (Supplementary Figure S3B) , in which the former was altered in our experimental settings (Table 2 ) and the latter was inhibited by ganetespib. It has been shown that RIP1 acts as a survival or necroptotic signal when the apoptosis pathway is blocked in TNFR1-activated cells.
30,31
Interestingly, we showed that doxorubicin upregulated, whereas ganetespib downregulated RIP1 in both H82 and GLC4 cells with western blot analysis ( Figure 3A) . As a control, 17-AAG, a geldanamycin derivative that is different in structure from ganetespib, could also suppress RIP1 expression in GLC4 cells, albeit to a lesser extent than ganetespib (Supplementary Figure S4) , indicating that the RIP1 inhibition was potentially the on-target effect of HSP90 inhibitions. This is in agreement with the stronger growth inhibitory potency of ganetespib as compared with 17-AAG as illustrated earlier.
To evaluate the significance of RIP1 upregulation in doxorubicintreated cells, we depleted RIP1 using small interfering RNA (siRNA)-mediated knockdown approach in doxorubicin-treated H82 and GLC4 cells ( Figure 3B ). Interestingly, knockdown of RIP1 by RIP1 no. 1 or no. 4 siRNAs sensitized doxorubicin-mediated cell death ( Figures 3C, D and Supplementary Figure S5 ) to a similar extent as ganetespib þ doxorubicin combination treatment (Figure 2A ), suggesting that RIP1 may confer a survival signal, and disruption of RIP1 may be essential in mediating the synergistic effect.
Synergistic effect of ganetespib and doxorubicin combination in SCLC xenograft model H82 xenografts in immunodeficient nude mice were treated with ganetespib and doxorubicin, both as single agent and combination. As shown in Figure 4A , weekly intravenous administration of the non-toxic dose 16, 19 of ganetespib of 150 mg/kg induced tumor regression with a T/C value of 36.1%. Doxorubicin single-agent treatment with 4 mg/kg intraperitoneally every other day had a T/C value of 38.9%. Consistent with the in vitro findings, combination treatment with the same comparable doses and schedules as its respective single agents resulted in a significantly improved tumor volume reduction with a T/C value of 14.1%. (Po0.0001; one-way ANOVA). This was accompanied by a prominent reduction in RIP1 expression in the combination group, which was apparently mediated by ganetespib treatment ( Figure 4B ) as documented in our in vitro studies ( Figure 3A) . Although not as prominent as in H82 xenografts, the combination treatment also significantly reduced tumor volumes with a %T/C value of 37.2 (Po0.008) in GLC4 xenograft experiments (Supplementary Figure S6) , validating our finding in another SCLC xenograft model system. Single-agent ganetespib was well tolerated with increase in body weight of 6.24%. The body weight loss of mice treated with single-agent doxorubicin and combination therapy were À 0.35 and À 5.04%, respectively (Supplementary Figure S7) .
Ganetespib and doxorubicin combination treatment causes more cell death than single agents in xenograft tumors
The xenografts were stained with hematoxylin and eosin (H&E). In xenografts treated with doxorubicin, there were extensive areas of necrosis, and similar rates of necrotic cells were found in tumors of ganetespib treatment group ( Figure 4C ). In addition, many cells of ganetespib-treated xenografts were larger in size with cytoplasmic vacuoles, indicative of G2/M arrest or dying cells. The presence of G2/M-arrested cells in ganetespib, doxorubicin and combination treatment groups were revealed by the accumulation of G2/M phase marker Survivin. 32 As documented in in vitro experiments (Figure 3A) , the response to HSP90 inhibition was monitored by HSP70 accumulation 18 ( Figure 4B ). Importantly, multisection evaluation of the H&E-stained slides showed that the doxorubicin þ ganetespib combination-treated cells looked smaller than the ganetespib-or doxorubicin-treated cells, which was in line with the finding that xenograft tumors in the combination treatment group exhibited higher rate of necrotic cells than either single-agent treatment groups ( Figure 4C ).
DISCUSSION
In this study, we demonstrated that ganetespib is a potent HSP90 inhibitor in SCLC cells and that ganetespib and doxorubicin are synergistic in vitro and in SCLC xenograft models. HSP90 inhibition initiates G1/G0 arrest in Rb-positive cells. In contrast to the DNA-damaging drug doxorubicin, inhibition of HSP90 in many Rb-negative cell lines has no effects on cell cycle progression or induces slight accumulation at the G2/M checkpoint. 33 Most of the SCLC cell lines employed in this study are Rb-negative (Supplementary Table S2 ). The fact that ganetespib elicited G2/M arrest in the tested SCLC cell lines raises the possibility that ganetespib, similar to doxorubicin, may cause DNA damage, which in turns triggers G2/M checkpoint arrest. However, we did not see significant induction of the DNA damage marker gH2AX in ganetespib-or 17-AAG-treated GLC4 and H82 cells (Supplementary Figsures S4 and S8 ), suggesting that ganetespib may not induce G2/M arrest via damaging DNA. Many G2/M regulators, such as Cyclin B, Cdc2 and Cdc25, are known HSP90 client proteins (www.picard.ch/downloads/Hsp90interactors.pdf). It remains to be investigated whether degradation of those regulatory proteins may also have a role in ganetespib-induced G2/M arrest.
Although previous studies showed that geldanamycin analogs DMAG and 17AAG synergized with doxorubicin by abrogating doxorubicin-induced G2/M arrest via downregulation of Chk1 followed by apoptosis in p53 mutant lymphoma and leukemia cell lines, 34, 35 contradictory results were reported in other p53-null HL60 and U937 cells. 36, 37 In this study, ganetespib synergized with doxorubicin in the absence of G2/M checkpoint abrogation in the p53 mutant/RB-negative H82 and H69 cells, suggesting that synergistic mechanism(s) may vary in different cell types.
In general, HSP90 inhibitor-induced cell cycle arrest has been thought to be reversible, although this issue has not been thoroughly addressed. In a subset of cancers, such as SCLC and multiple myeloma cells, it has been shown that HSP90 inhibitors induce apoptosis. 22, 38 We observed the following two distinct responses to ganetespib: cell cycle arrest and cell death. Ganetespib-induced G2/M arrest was persistent 72 h after drug washout or 6 days from the start of drug treatment (Figure 1d ). It is plausible that the high potency of ganetespib in most of the cancer cell lines tested 17, 18, 39, 40 may in part be attributed to its persistent cell cycle arrest.
RIP1 is an HSP90 client protein 13 and is known to interact with FADD. 29 FADD Ser194 phosphorylation was altered in all the treatment groups in our study (Table 2) . Ingenuity pathway analysis of our RPPA data revealed that RIP1 may be involved in the apoptotic/necroptotic response of doxorubicin-and ganetaspib-treated SCLC cells. In line with this, we showed that RIP1 expression was upregulated in doxorubicin-treated SCLC cells. Depletion of RIP1 by siRNA enhanced cell death induced by doxorubicin, suggesting that the role of RIP1 in this experimental setting may be to mediate a survival signal. As the disruption of HSP90 function by ganetespib caused significant reduction in RIP1 expression ( Figure 3A) , one of the potential mechanisms by which ganetespib synergizes with doxorubicin in inhibiting SCLC cell growth may be through downregulation of RIP1. High expression of RIP1 has been reported to contribute to resistance to tumor necrosis factor-alpha-induced apoptosis through activation of the NFkB pathway, 13 probably via regulation of IkB degradation. 41 Doxorubicin has been reported to induce NFkB activation, which may render cells either resistant 7 or sensitive 42 to the drug. It is conceivable that ganetespib could counteract the effect of doxorubicin on NFkB activity, as western blot analysis revealed that doxorubicin modestly decreased and ganetespib increased the abundance of IkB-a, an inhibitor of the NFkB pathway 41 in GLC4 cells (Supplementary Figure S9A) . However, siRNAmediated RIP1 depletion did not significantly alter the abundance of IkB-a (Supplementary Figure S9B) , suggesting that the negative effect of ganetespib on NFkB activation, if any, may not require RIP1. How the downregulation of RIP1 by ganetespib may have a role in doxorubicin sensitization will require additional investigation. Taken altogether, our data suggest that ganetespib may sensitize doxorubicin-induced cell death in part through the inhibition of RIP1 activity and induction of the persistent G2/M phase arrest.
Combination chemotherapy remains the mainstay treatment for most tumors. Standard first-line chemotherapy regimens for SCLC include platinum-containing doublet regimens (etoposide and cisplatin or carboplatin, and irinotecan and cisplatin mainly in Japan) 43, 44 and also doxorubicin-containing regimens (cyclophosphamide, doxorubicin and vincristine; cyclophosphamide and vincristine; 45, 46 and cyclophosphamide, doxorubicin, etoposide). 43, 44 Platinum doublets have been preferred more recently because of easier co-administration with radiation therapy in patients with limited disease. SCLC patients are highly sensitive to initial chemotherapy; however, the overall prognosis has improved little over the past two decades mainly because the response to treatment is often short and the prognosis of relapsed patients who receive second-line therapy, such as topotecan or cyclophosphamide and vincristine, is poor. 1, 47 The novel anthracycline amrubicin has been shown to have definite antitumor activity in platinum-refractory SCLC; 48 however, randomized studies in second line and first line have failed to show significant advantages against standard chemotherapy.
49
The mechanisms of resistance to chemotherapies are still largely unknown, 50 and there is an urgent need to develop more effective first-and second-line therapeutic regimens that would circumvent these resistant mechanisms. In this study, we showed that ganetespib and doxorubicin combination exhibited significant synergy in inhibiting the growth of SCLC cells in vitro and in mouse xenografts. The efficacy of the combination treatment and the potential involvement of RIP1 to mediate the synergy discovered in this study suggest that ganetespib may enhance the effects of doxorubicin and potentially attenuate the occurrence of resistance. Clinical studies of a combination of ganetespib and doxorubicin are warranted in SCLC patients with extensive disease.
MATERIALS AND METHODS
Cell lines and drugs
All SCLC cell lines (GLC4, NCI-H82, NCI-H69, NCI-H128, NCI-H146, NCI-H187, NCI-H526, NCI-N592, NCI-H620, NCI-H792, NCI-H1173 and AC-3) were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum at 37 1C in 5% CO 2 incubator. Cell viability was assessed with Trypan Blue staining (Life Technologies, Grand Island, NY, USA). Doxorubicin (LC Laboratories, Woburn, MA, USA), etoposide (Sigma-Aldrich, St Louis, MO, USA) and ganetespib (STA-9090) (Synta Pharmaceuticals) were dissolved in dimethylsulfoxide according to the manufacturer's instructions.
Cell cycle analysis
Cells were seeded in 25-cm 2 flasks at a density of 2 Â 10 5 cells/ml. Before collection, cells were washed with cold phosphate-buffered saline (PBS) and fixed with cold 70% ethanol in PBS followed by centrifugation. Cell pellets were resuspended in 500 ml propidium iodine in PBS (10 mg/ml) containing 300 mg/ml RNase (Qiagen, Valencia, CA, USA). Cells were then incubated for 30 min with gentle shaking and filtered with 40 mm nylon mesh (BD Falcon, CA, USA). Cells were acquired with FACScalibur using Cellquest Pro software (Becton Dickinson and Company, Franklin Lakes, NJ, USA) and cell cycle distributions were analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA). 
TO-PRO-3 viability assay
A total of 10 6 cells were harvested using centrifugation and washed in PBS twice. TO-PRO 3 iodide (Life Technologies) was added at a final concentration of 500 nM to the cells in PBS immediately before analysis. Cells were acquired using a FACSCalibur flow cytometer (Beckton Dickinson) and analyzed with the help of FlowJo (Tree Star, Ashland, OR, USA).
MTS assay
Briefly, 20 000 cells in 200 ml media were dispensed into each well of 96-well flat-bottom plates. Plates were subsequently incubated for 72 h with different concentrations of drugs. A total of 10 ml of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet razolium) reagent was added to each well. Two or three hours later, absorbance at 490 nm was measured by a multiwell plate reader (Molecular Devices, Sunnyvale, CA, USA). Experiments were repeated at least three times. The cell viability was obtained by normalizing the absorbance of the treated samples with that of the controls and expressed as percentage, assigning the viability of non-treated cells as 100%. Survival curves were constructed using Prism V5.0 (GraphPad Software, La Jolla, CA, USA), and IC50s were calculated.
Cytotoxic combination effects of doxorubicin, etoposide and ganetespib were assessed with seven different concentrations of drugs (3.75, 2.25, 1.5, 1, 0.67, 0.44 and 0.27 Â IC50). CIs were calculated using CalcuSyn (Biosoft, Cambridge, UK). The Chou-Talalay method was used, which defines additive effect (CI ¼ 1), synergism (CIo1) and antagonism (CI41) of drug combinations. 51 Western blot and antibodies Following treatment, tumor cells were harvested, centrifuged and washed with cold PBS. Lysates were prepared with RIPA buffer on ice, equal amounts of proteins were dissolved in SDS-PAGE and western blot was performed as described previously. 52 The intensities of band signals were assessed using GeneTools software (SynGene, Frederick, MD, USA) and normalized by the intensity of a-tubulin. All antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).
In vivo xenograft tumor models and drug administrations Two-week-old athymic immunodeficient nude mice were maintained in the pathogen-free facilities of the National Institutes of Health (NIH) and cared in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Mice were subcutaneously implanted with 8 Â 10 6 NCI-H82 or GLC4 cells and left to grow for 2 weeks to a volume of about 80-100 mm 3 . Eligible mice were randomized into treatment groups of eight. Doxorubicin was administered by intraperitoneal injection of 4 mg/kg, three times a week for 3 weeks. Ganetespib (STA-12-1474 for in vivo study from Synta Pharmaceuticals), 16, 20 formulated in PBS and pH-adjusted to neutral just before use in order to prevent precipitation, was injected intravenously via the tail vein. Mice were treated with ganetespib at 150 mg/kg weekly for 3 weeks.
Animals were closely monitored, and body weight and tumor volume were measured three times a week. Tumor volumes were calculated using V ¼ ½(L Â W 2 ) formula. The T/C value was determined from changes in average tumor volumes of drug-treated groups relative to vehicle-treated groups.
TUNEL stain Approximately 10 6 cells treated with 40 nM doxorubicin, 30 nM ganetespib and 40 nM doxorubicin þ 30 nM ganetespib combination or vehicle were harvested, centrifuged, washed in PBS, resuspended with 30 ml PBS and added to poly-L-lysine-coated slides and left to air-dry in a tissue culture hood for B1-2 h before fixation. The TUNEL was performed using the DeadEnd Colorimetric TUNEL System Kit (Promega, Madison, WI, USA), following the manufacturer's protocol.
RPPA analysis H82 cells were treated with 40 nM doxorubicin, 30 nM ganetespib, 250 nM etoposide, the combination of 40 nM doxorubicin þ 30 nM ganetespib or 250 nM etoposide þ 30 nM ganetespib for 24 and 48 h, respectively. Cell lysates were prepared as previously described. 53 Samples derived from drug treatment and control groups were printed in triplicates onto the same arrays of nitrocellulose-coated slides and probed with 113 antibodies targeting cancer-associated total and phosphorylated proteins, respectively, as described previously. 24, 25 Final signal intensities were obtained after background, secondary antibody subtraction and normalization to the total amount of protein present in each individual samples. 53 
Statistical analysis
Statistical analysis was performed using SPSS version 17.0 (SPSS, Chicago, IL, USA) or GraphPad Prism V5.0 (GraphPad Software). Comparisons of categorical variables between the different groups were made using the w 2 test or Fisher's exact test, when the number of cases was fewer than five. The paired Student's t-test for continuous variables was performed for the means between paired groups. Comparison of drug efficacy and potency in different treatment groups was carried out by one-way ANOVAs. All P-values were two-sided, and P-values of o0.05 were regarded as significant. For RPPA data analysis, the Ward method for two-way unsupervised hierarchical clustering was performed using JMP v5.1 (SAS Institute, Cary, NC, USA). One-way ANOVA with Dunnett's Multiple Comparison Test (Prism v5.0b, GraphPad Software) was applied to compare values of the treatment groups with those of the control group. P-values o0.05 were considered statistically significant.
